vs
Side-by-side financial comparison of Claritev Corp (CTEV) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Claritev Corp is the larger business by last-quarter revenue ($246.6M vs $129.7M, roughly 1.9× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 6.2%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 2.5%).
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
CTEV vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $246.6M | $129.7M |
| Net Profit | $-80.6M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | -3.1% | -25.0% |
| Net Margin | -32.7% | — |
| Revenue YoY | 6.2% | 73.4% |
| Net Profit YoY | 41.6% | — |
| EPS (diluted) | $-4.88 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $246.6M | $129.7M | ||
| Q3 25 | $246.0M | $164.9M | ||
| Q2 25 | $241.6M | $114.4M | ||
| Q1 25 | $231.3M | $81.7M | ||
| Q4 24 | $232.1M | $74.8M | ||
| Q3 24 | $230.5M | $62.9M | ||
| Q2 24 | $233.5M | $54.1M | ||
| Q1 24 | $234.5M | $41.4M |
| Q4 25 | $-80.6M | — | ||
| Q3 25 | $-69.8M | $25.7M | ||
| Q2 25 | $-62.6M | $-12.8M | ||
| Q1 25 | $-71.3M | $-41.2M | ||
| Q4 24 | $-138.0M | — | ||
| Q3 24 | $-391.4M | $-54.8M | ||
| Q2 24 | $-576.7M | $-70.4M | ||
| Q1 24 | $-539.7M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -3.1% | -25.0% | ||
| Q3 25 | 4.1% | 15.1% | ||
| Q2 25 | 6.9% | -11.1% | ||
| Q1 25 | 4.2% | -52.2% | ||
| Q4 24 | -17.8% | -81.2% | ||
| Q3 24 | -146.7% | -89.3% | ||
| Q2 24 | -224.4% | -125.1% | ||
| Q1 24 | -207.4% | -336.5% |
| Q4 25 | -32.7% | — | ||
| Q3 25 | -28.4% | 15.6% | ||
| Q2 25 | -25.9% | -11.1% | ||
| Q1 25 | -30.8% | -50.4% | ||
| Q4 24 | -59.4% | — | ||
| Q3 24 | -169.8% | -87.1% | ||
| Q2 24 | -247.0% | -130.1% | ||
| Q1 24 | -230.1% | -328.9% |
| Q4 25 | $-4.88 | $0.04 | ||
| Q3 25 | $-4.23 | $0.28 | ||
| Q2 25 | $-3.81 | $-0.14 | ||
| Q1 25 | $-4.38 | $-0.47 | ||
| Q4 24 | $-8.49 | $-0.71 | ||
| Q3 24 | $-24.25 | $-0.70 | ||
| Q2 24 | $-35.78 | $-0.91 | ||
| Q1 24 | $-33.40 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.8M | $93.0M |
| Total DebtLower is stronger | $4.6B | — |
| Stockholders' EquityBook value | $-173.9M | $114.8M |
| Total Assets | $4.9B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.8M | $93.0M | ||
| Q3 25 | $39.2M | $110.9M | ||
| Q2 25 | $56.4M | $75.2M | ||
| Q1 25 | $23.1M | $61.9M | ||
| Q4 24 | $16.8M | $58.5M | ||
| Q3 24 | $86.6M | $36.4M | ||
| Q2 24 | $48.8M | $32.3M | ||
| Q1 24 | $58.7M | $43.3M |
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $-173.9M | $114.8M | ||
| Q3 25 | $-101.8M | $73.6M | ||
| Q2 25 | $-39.9M | $32.7M | ||
| Q1 25 | $14.8M | $32.8M | ||
| Q4 24 | $84.0M | $59.1M | ||
| Q3 24 | $207.6M | $-30.5M | ||
| Q2 24 | $603.4M | $15.1M | ||
| Q1 24 | $1.2B | $74.1M |
| Q4 25 | $4.9B | $605.2M | ||
| Q3 25 | $5.0B | $538.6M | ||
| Q2 25 | $5.1B | $555.3M | ||
| Q1 25 | $5.1B | $548.8M | ||
| Q4 24 | $5.2B | $594.1M | ||
| Q3 24 | $5.3B | $504.4M | ||
| Q2 24 | $5.7B | $551.1M | ||
| Q1 24 | $6.4B | $663.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $66.3M | $60.7M |
| Free Cash FlowOCF − Capex | $36.4M | — |
| FCF MarginFCF / Revenue | 14.8% | — |
| Capex IntensityCapex / Revenue | 12.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-12.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.3M | $60.7M | ||
| Q3 25 | $19.9M | $14.3M | ||
| Q2 25 | $61.2M | $5.0M | ||
| Q1 25 | $-30.1M | $-42.2M | ||
| Q4 24 | $-33.4M | $-35.7M | ||
| Q3 24 | $72.8M | $-42.5M | ||
| Q2 24 | $18.5M | $-40.2M | ||
| Q1 24 | $49.7M | $-119.0M |
| Q4 25 | $36.4M | — | ||
| Q3 25 | $-16.3M | $14.2M | ||
| Q2 25 | $36.6M | — | ||
| Q1 25 | $-68.9M | — | ||
| Q4 24 | $-63.8M | — | ||
| Q3 24 | $41.1M | — | ||
| Q2 24 | $-7.0M | $-40.3M | ||
| Q1 24 | $19.2M | — |
| Q4 25 | 14.8% | — | ||
| Q3 25 | -6.6% | 8.6% | ||
| Q2 25 | 15.2% | — | ||
| Q1 25 | -29.8% | — | ||
| Q4 24 | -27.5% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | -3.0% | -74.5% | ||
| Q1 24 | 8.2% | — |
| Q4 25 | 12.1% | — | ||
| Q3 25 | 14.7% | 0.1% | ||
| Q2 25 | 10.2% | — | ||
| Q1 25 | 16.8% | — | ||
| Q4 24 | 13.1% | — | ||
| Q3 24 | 13.8% | 0.0% | ||
| Q2 24 | 10.9% | 0.2% | ||
| Q1 24 | 13.0% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTEV
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
